Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En forskningsstudie som sammenligner hvor godt ulike doser av medisinen NN0519-0130 senker blodsukkeret hos personer med type 2-diabetes

18. september 2026 oppdatert av: Novo Nordisk A/S

Undersøkelse av sikkerheten og effekten av NNC0519-0130 én gang i uken hos deltakere med type 2-diabetes – en dosefinnende studie

This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

299

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • New South Wales
      • Campbelltown, New South Wales, Australia, 2560
        • Campbelltown Hospital
      • Macquarie Park, New South Wales, Australia, 2109
        • Macquarie University - Clinical Trials Unit
      • St Leonards, New South Wales, Australia, 2065
        • Royal North Shore Hospital
      • Sydney, New South Wales, Australia, 2148
        • Western Endocrine Blacktown
      • Sydney, New South Wales, Australia, 2148
        • Roger Chih Yu Chen
      • Wollongong, New South Wales, Australia, 2500
        • Illawarra Diabetes Service Clinical Trials & Research Unit
    • Queensland
      • Birtinya, Queensland, Australia, 4575
        • University of Sunshine Coast - Vitality Village
      • Meadowbrook, Queensland, Australia, 4131
        • Logan Hospital
    • South Australia
      • Oaklands Park, South Australia, Australia, 5046
        • Southern Adelaide Diabetes & Endocrine Services
    • Victoria
      • Box Hill, Victoria, Australia, 3128
        • Eastern Clinical Research Unit Box Hill
      • Camberwell, Victoria, Australia, 3124
        • Emeritus Research Melbourne
      • Heidelberg Heights, Victoria, Australia, 3081
        • Austin Health, Metabolic Disorders Centre
      • Parkville, Victoria, Australia, 3050
        • The Royal Melbourne Hospital
      • Parkville, Victoria, Australia, 3050
        • The Royal Melbourne Hospital - Diabetes & Endocrinology Department
    • Western Australia
      • Fremantle, Western Australia, Australia, 6160
        • Fremantle Hospital
      • Québec, Canada, G1V 4T3
        • Diex Recherche Quebec
    • British Columbia
      • Kelowna, British Columbia, Canada, V1Y 1Z9
        • OCT Research ULC (dba Okanagan Clinical Trials)
      • Richmond, British Columbia, Canada, V6V 2L1
        • OCT Research ULC (dba Okanagan Clinical Trials)
      • Victoria, British Columbia, Canada, V8V 4A1
        • Cook Street Medical Clinic
    • New Brunswick
      • Moncton, New Brunswick, Canada, E1G 1A7
        • G.A. Research Associates Ltd.
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3H 1V7
        • Nova Scotia Hlth Halifax
    • Ontario
      • Barrie, Ontario, Canada, L4N 7L3
        • Centricity Research Barrie
      • Hamilton, Ontario, Canada, L8L 5G8
        • Wharton Medical Clinic Clinical Trials (Hamilton)
      • Sarnia, Ontario, Canada, N7T 4X3
        • London Road Diagnostic Clinic and Medical Centre
      • Toronto, Ontario, Canada, M4G 3E8
        • Centricity Research Toronto
      • Toronto, Ontario, Canada, M9V 4B4
        • Albion Finch Medical Centre
    • Quebec
      • Lévis, Quebec, Canada, G6W 0M5
        • Centricity Research Quebec City
      • Mirabel, Quebec, Canada, J7J 2K8
        • Centricity Research Mirabel
      • Montreal, Quebec, Canada, H1Y 3H5
        • Recherche GCP Research
      • Saint-Laurent, Quebec, Canada, H4T 1Z9
        • Centricity Research Ville St. Laurent VSL
    • California
      • Chula Vista, California, Forente stater, 91911
        • Velocity Clin Res-Chula Vista
      • Fresno, California, Forente stater, 93720
        • Valley Research
      • Inglewood, California, Forente stater, 90301
        • 310 Clinical Research
      • La Mesa, California, Forente stater, 91942
        • Velocity Clin Res San Diego
      • Lancaster, California, Forente stater, 93534
        • First Valley Med Grp Lancaster
      • Lomita, California, Forente stater, 90717
        • Torrance Clin Res Inst, Inc.
      • Los Alamitos, California, Forente stater, 90720
        • Pacific Clinical Studies
      • Los Angeles, California, Forente stater, 90057
        • Velocity Clinical Research Westlake
      • Montclair, California, Forente stater, 91763
        • Catalina Research Institute, LLC
      • San Diego, California, Forente stater, 92123
        • Artemis Insitute for Clin Res
      • Toluca Lake, California, Forente stater, 91602
        • Med Partners, Inc.
      • Torrance, California, Forente stater, 90505
        • UCLA Health Southbay Endocrine
      • Tustin, California, Forente stater, 92780
        • University Clin Investigators
      • Walnut Creek, California, Forente stater, 94598
        • Diablo Clinical Research, Inc.
    • Colorado
      • Aurora, Colorado, Forente stater, 80045
        • University of Colorado Hospital
    • Florida
      • Clearwater, Florida, Forente stater, 33756
        • Innovative Research of W Florida Inc.
      • Clearwater, Florida, Forente stater, 33756
        • Innovative Research of W FL
      • Miami, Florida, Forente stater, 33183
        • International Research Associates, LLC_Miami
    • Georgia
      • Columbus, Georgia, Forente stater, 31904
        • Centricity Research
    • Idaho
      • Blackfoot, Idaho, Forente stater, 83221
        • Elite Clinical Trials
    • Illinois
      • Peoria, Illinois, Forente stater, 61603
        • Methodist Medical Center of Illinois
    • Iowa
      • Iowa City, Iowa, Forente stater, 52242
        • University of Iowa
    • Maryland
      • Columbia, Maryland, Forente stater, 21045
        • Centennial Medical Group
      • Oxon Hill, Maryland, Forente stater, 20745
        • MD Medical Research
      • Rockville, Maryland, Forente stater, 20852
        • Endo And Metab Cons
    • Missouri
      • Springfield, Missouri, Forente stater, 65807
        • Clinvest Research
    • Montana
      • Butte, Montana, Forente stater, 59701
        • Mercury Str Med Grp, PLLC
    • Nebraska
      • Lincoln, Nebraska, Forente stater, 68510
        • Velocity Clinical Research Lincoln
    • Nevada
      • Las Vegas, Nevada, Forente stater, 89148
        • Palm Research Center Inc-Vegas
      • Las Vegas, Nevada, Forente stater, 89109
        • Excel Clinical Network
    • New York
      • Binghamton, New York, Forente stater, 13905
        • Velocity Clinical Research Binghamton
    • North Carolina
      • Greensboro, North Carolina, Forente stater, 27408
        • PharmQuest Life Sciences LLC
      • Wilmington, North Carolina, Forente stater, 28401
        • Accellacare Wilmington
    • Ohio
      • Canton, Ohio, Forente stater, 44718
        • Diab & Endo Assoc of Stark Co
      • Cincinnati, Ohio, Forente stater, 45242
        • Velocity Clin Res_Cincinnati
      • Cincinnati, Ohio, Forente stater, 45246
        • Velocity Clinical Research Springdale
      • Dayton, Ohio, Forente stater, 45439
        • Providence Health Partners Ctr
      • Maumee, Ohio, Forente stater, 43537
        • Advanced Med Res Maumee
    • Oregon
      • Grants Pass, Oregon, Forente stater, 97527
        • Velocity Clin Res Grants Pass
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19114
        • Tristar Clin Investigations, PC
      • Pittsburgh, Pennsylvania, Forente stater, 15243
        • Preferred Primary Care Physicians Inc.
      • Uniontown, Pennsylvania, Forente stater, 15401
        • Preferred Primary Care Physicians, Inc.
    • Texas
      • Abilene, Texas, Forente stater, 79606
        • Velocity Clinical Research Abilene
      • Austin, Texas, Forente stater, 78759
        • Velocity Clin Res Austin
      • Dallas, Texas, Forente stater, 75390
        • UT Southwestern Med Center
      • Dallas, Texas, Forente stater, 75230
        • Velocity Clinical Res-Dallas
      • Dallas, Texas, Forente stater, 75230
        • Zenos Clinical research
      • Forney, Texas, Forente stater, 75126
        • Care United Research, LLC
      • Houston, Texas, Forente stater, 77004
        • Endocrine Associates Houston
      • Houston, Texas, Forente stater, 77043
        • Biopharma Informatic_Houston
      • Irving, Texas, Forente stater, 75039
        • Tekton Research
      • Lewisville, Texas, Forente stater, 75057
        • Epic Clinical Research
      • Shavano Park, Texas, Forente stater, 78231
        • Consano Clinical Research, LLC
    • Virginia
      • Burke, Virginia, Forente stater, 22015
        • Burke Internal Medicine & Research
      • Newport News, Virginia, Forente stater, 23606
        • TPMG Clinical Research
      • Bengaluru, India, 560054
        • MS Ramaiah
      • New Delhi, India, 110001
        • Lady Hardinge Medical College
    • Karnataka
      • Bangalore, Karnataka, India, 560092
        • Life Care Hospital and Research Centre
    • Kerala
      • Kochi, Kerala, India, 682041
        • Amrita Institute Of Medical Sciences & Research Centre
    • Madhya Pradesh
      • Indore, Madhya Pradesh, India, 452010
        • TOTALL Diabetes Hormone Institute
    • Maharashtra
      • Mumbai, Maharashtra, India, 400012
        • Seth GS Medical College & KEM Hospital
      • Pune, Maharashtra, India, 411021
        • Chellaram Diabetes Institute
    • Rajasthan
      • Jaipur, Rajasthan, India, 302006
        • Diabetes, Thyroid and Endocrine Centre
    • Tamil Nadu
      • Vellore, Tamil Nadu, India, 632004
        • Christian Medical College Hospital, Vellore
    • Telangana
      • Hyderabad, Telangana, India, 500082
        • Diabetes Research Center, Hyderabad
      • Chiba, Japan, 261-0004
        • Tokuyama clinic_Diabetic internal medicine
      • Soka-shi, Saitama, Japan, 340-0015
        • Soka Sugiura Internal Medicine Clinic
      • Tokyo, Japan, 104-0031
        • Fukuwa Clinic
      • Tokyo, Japan, 103-0027
        • Tokyo-Eki Center-building Clinic_Internal Medicine
      • Tokyo, Japan, 104-0031
        • Fukuwa Clinic_Internal Medicine
      • Seoul, Sør -Korea, 05505
        • Asan Medical Center
      • Seoul, Sør -Korea, 01830
        • Nowon Eulji Medical Center, Eulji University
      • Seoul, Sør -Korea, 03181
        • Kangbuk Samsung Hospital
      • Seoul, Sør -Korea, 02841
        • Korea University Anam Hospital
    • Gyeonggi-do
      • Seongnam-si, Gyeonggi-do, Sør -Korea, 13620
        • Seoul National University Bundang Hospital
    • Free State
      • Bloemfontein, Free State, Sør-Afrika, 9301
        • Josha Research
    • Gauteng
      • Johannesburg, Gauteng, Sør-Afrika, 2013
        • Wits Bara Clinical Trial Site
      • Midrand, Gauteng, Sør-Afrika, 1685
        • Dr A Jacovides and Partners Inc
    • KwaZulu-Natal
      • Durban, KwaZulu-Natal, Sør-Afrika, 4450
        • Dr Pillay's Rooms
      • eMkhomazi, KwaZulu-Natal, Sør-Afrika, 4170
        • Dr T Padayachee

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Female of non-childbearing potential, or male.
  • For United States (US) only: Female of childbearing potential using highly effective non-systemic methods of contraception with low user-dependency and willingness to continue using it through-out the study or male.
  • Age 18-75 years (both inclusive) at the time of signing the informed consent.
  • Diagnosed with type 2 diabetes mellitus greater than or equal 180 days before screening.
  • Stable daily dose(s) more than or equal 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without sodium-glucose co-transporter 2 (SGLT2) inhibitor.
  • Glycated haemoglobin (HbA1c) of 7.5-10.0% (58-86 millimoles per moles (mmol/mol)) (both inclusive) as assessed by central laboratory at screening.
  • Body mass index (BMI) greater than or equal 23.0 kilograms per meter square (kg/m^2).

Exclusion Criteria:

  • Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
  • Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Dosing scheme A (NNC0519-0130)

Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as subcutaneous (s.c.) injection in dose escalating manner.

NNC0519-0130 will be administered subcutaneously.

Placebo komparator: Dosing scheme A (Placebo)

Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.

Placebo will be administered subcutaneously.

Eksperimentell: Dosing scheme B (NNC0519-0130)

Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as s.c. injection in dose escalating manner.

NNC0519-0130 will be administered subcutaneously.

Placebo komparator: Dosing scheme B (Placebo)

Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.

Placebo will be administered subcutaneously.

Eksperimentell: Dosing scheme C (NNC0519-0130)

Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner.

NNC0519-0130 will be administered subcutaneously.

Placebo komparator: Dosing scheme C (Placebo)

Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.

Placebo will be administered subcutaneously.

Eksperimentell: Dosing scheme D (NNC0519-0130)

Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner.

NNC0519-0130 will be administered subcutaneously.

Placebo komparator: Dosing scheme D (Placebo)

Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.

Placebo will be administered subcutaneously.

Eksperimentell: Dosing scheme E (NNC0519-0130)

Participants will receive NNC0519-0130 at 7 dose levels once weekly as s.c. injection in dose escalating manner.

NNC0519-0130 will be administered subcutaneously.

Placebo komparator: Dosing scheme E (Placebo)

Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods.

Placebo will be administered subcutaneously.

Aktiv komparator: Dosing scheme F (tirzepatide)

Participants will receive tirzepatide at 6 dose levels once weekly as s.c. injection in dose escalating manner.

Trizepatide will be administered subcutaneously.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Glycated haemoglobin (HbA1c)
Tidsramme: From baseline (week 0) to 12 weeks on a given maintenance dose

Measured as percentage point (%-point)

From baseline (week 0) to 12 weeks on a given maintenance dose

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Glycated haemoglobin (HbA1c)
Tidsramme: From baseline (week 0) to end of treatment (week 36)

Measured as percentage point (%-point)

From baseline (week 0) to end of treatment (week 36)
Relative change in body weight
Tidsramme: From baseline (week 0) to end of treatment (week 36)

Measured as percentage (%)

From baseline (week 0) to end of treatment (week 36)
Change in body weight
Tidsramme: From baseline (week 0) to end of treatment (week 36)

Measured as kilograms (kg)

From baseline (week 0) to end of treatment (week 36)
Change in fasting plasma glucose (FPG)
Tidsramme: From baseline (week 0) to 12 weeks on a given maintenance dose

Measured as millimoles per liter (mmol/L)

From baseline (week 0) to 12 weeks on a given maintenance dose
Continuous glucose monitoring (CGM): Change in time in range (TIR) 3.9-10.0 millimoles per liter (mmol/L) (70-180 milligrams per deciliter (mg/dL))
Tidsramme: From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively

Measured as percentage point (%-point)

From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively
Change in waist circumference
Tidsramme: From baseline (week 0) to end of treatment (week 36)

Measured as centimeter (cm)

From baseline (week 0) to end of treatment (week 36)
Change in systolic blood pressure (SBP)
Tidsramme: From baseline (week 0) to end of treatment (week 36)

Measured as millimeters of mercury (mmHg)

From baseline (week 0) to end of treatment (week 36)
Change in high sensitivity C-Reactive Protein (hsCRP)
Tidsramme: From baseline (week 0) to end of treatment (week 36)

Measured as ratio to baseline

From baseline (week 0) to end of treatment (week 36)
Change in total cholesterol
Tidsramme: From baseline (week 0) to end of treatment (week 36)

Measured as ratio to baseline

From baseline (week 0) to end of treatment (week 36)
Change in high-density lipoprotein (HDL) cholesterol
Tidsramme: From baseline (week 0) to end of treatment (week 36)

Measured as ratio to baseline

From baseline (week 0) to end of treatment (week 36)
Change in low-density lipoprotein (LDL) cholesterol
Tidsramme: From baseline (week 0) to end of treatment (week 36)

Measured as ratio to baseline

From baseline (week 0) to end of treatment (week 36)
Change in triglycerides
Tidsramme: From baseline (week 0) to end of treatment (week 36)

Measured as ratio to baseline

From baseline (week 0) to end of treatment (week 36)
Number of adverse events
Tidsramme: From baseline (week 0) to end of study (week 40)

Measured as number of events

From baseline (week 0) to end of study (week 40)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Clinical Transparency (dept. 2834), Novo Nordisk A/S

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

18. mars 2024

Primær fullføring (Faktiske)

19. september 2025

Studiet fullført (Faktiske)

13. oktober 2025

Datoer for studieregistrering

Først innsendt

16. mars 2024

Først innsendt som oppfylte QC-kriteriene

16. mars 2024

Først lagt ut (Faktiske)

22. mars 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

21. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

18. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • NN9541-4945
  • U1111-1291-9196 (Annen identifikator: World Health Organization (WHO))
  • jRCT2031230704 (Registeridentifikator: JRCT)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere